CLAL BIOTECHNOLOGY INDUSTRIES LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.6 ILa | -1.17% |
|
+3.90% | +27.46% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 370K 99.56K 37M | Sales 2023 | 104K 27.98K 10.4M | Capitalization | 62.27M 16.75M 6.23B |
|---|---|---|---|---|---|
| Net income 2022 | -61M -16.41M -6.1B | Net income 2023 | -31M -8.34M -3.1B | EV / Sales 2022 | 331 x |
| Net Debt 2022 | 23.85M 6.42M 2.38B | Net Debt 2023 | 22.4M 6.03M 2.24B | EV / Sales 2023 | 814 x |
| P/E ratio 2022 |
-1.6
x | P/E ratio 2023 |
-2.01
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 34.65% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.17% | ||
| 1 week | +3.90% | ||
| Current month | +6.53% | ||
| 1 month | +19.91% | ||
| 3 months | +37.13% | ||
| 6 months | +8.58% | ||
| Current year | +27.46% |
1 week
48.60
53.00
1 month
41.1053.00
Current year
36.6053.00
1 year
36.6063.00
3 years
36.60267.80
5 years
36.60278.00
10 years
36.60980.00
| Managers | Title | Age | Since |
|---|---|---|---|
Assaf Segal
CEO | Chief Executive Officer | 51 | 15-06-30 |
Liat Nissan
DFI | Director of Finance/CFO | 46 | - |
Arnon Aharon
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 03-05-08 | |
Yuval Yanai
BRD | Director/Board Member | 71 | 15-11-17 |
Gad Keren
BRD | Director/Board Member | 73 | 20-02-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 50.6 | -1.17% | 24 027 |
| 24-05-07 | 51.2 | +0.20% | 166,788 |
| 24-05-06 | 51.1 | +0.59% | 14,111 |
| 24-05-05 | 50.8 | +0.59% | 44,975 |
| 24-05-02 | 50.5 | +3.70% | 92,267 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 08, 2024 at 08:19 am EDT
More quotes
Clal Biotechnology Industries Ltd (CBI) is an Israel-based biotechnology investment company. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The Company is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.
Sector
Investment Holding Companies
| 1st Jan change | Capi. | |
|---|---|---|
| +27.46% | 21.7M | |
| +20.00% | 79.03B | |
| +63.68% | 18.55B | |
| +7.28% | 16.58B | |
| +8.97% | 14.35B | |
| +2.43% | 12.87B | |
| +8.61% | 11.96B | |
| +9.03% | 11.03B | |
| +35.87% | 10.4B | |
| +0.95% | 9.92B |
- Stock Market
- Equities
- CBI Stock